The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Kumar, Eric A ^a   Chen, Qianyi ^a   Kizhake, Smitha ^a   Kolar, Carol ^a   Kang, Myungshim ^b   Chang, Chia En A ^b   Borgstahl, Gloria E O ^a   Natarajan, Amarnath ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CBL PROTEIN; LIGAND; PEPTIDE;

AMINO ACID SEQUENCE; ARTICLE; BINDING SITE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; HYDROGEN BOND; KINETICS; METABOLISM; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN BINDING;

AMINO ACID SEQUENCE; BINDING SITES; HYDROGEN BONDING; KINETICS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PEPTIDES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-CBL;

EID: 84902940152     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01639     Document Type: Article

References (52)

1. Oltersdorf, T. et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435, 677-681 (2005).
2. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
3. Pflugrath, J. W. The finer things in X-ray diffraction data collection. Acta Crystallogr D Biol Crystallogr 55, 1718-1725 (1999).
4. Arkin, M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov 3, 301-317 (2004).
5. Joseph, P. R. et al. Structural characterization of BRCT-tetrapeptide binding interactions. Biochem Biophys Res Commun 393, 207-210 (2010).
6. Kussie, P. H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
7. Mullard, A. Protein-protein interaction inhibitors get into the groove. Nat Rev Drug Discov 11, 173-175 (2012).
8. Shakespeare, W. C. SH2 domain inhibition: a problem solved? Curr Opin Chem Biol 5, 409-415 (2001).
9. Baek, S. et al. Structure ofthe stapled p53 peptide bound toMdm2. J AmChem Soc 134, 103-106 (2011).
10. Udugamasooriya, G., Saro, D. & Spaller, M. R. Bridged peptide macrocycles as ligands for PDZ domain proteins. Org Lett 7, 1203-1206 (2005).
11. Patgiri, A., Jochim, A. L. & Arora, P. S. A hydrogen bond surrogate approach for stabilization of short peptide sequences in alpha-helical conformation. Acc Chem Res 41, 1289-1300 (2008).
12. Wang, D., Liao, W. & Arora, P. S. Enhanced metabolic stability and proteinbinding properties of artificial alpha helices derived from a hydrogen-bond surrogate: application to Bcl-xL. Angew Chem Int Ed Engl 44, 6525-6529 (2005).
13. Vagner, J., Qu, H. & Hruby, V. J. Peptidomimetics, a synthetic tool of drug discovery. Curr Opin Chem Biol 12, 292-296 (2008).
14. Henchey, L. K., Porter, J. R., Ghosh, I. & Arora, P. S. High specificity in protein recognition by hydrogen-bond-surrogate alpha-helices: selective inhibition of the p53/MDM2 complex. Chembiochem 11, 2104-2107 (2010).
15. DeLorbe, J. E. et al. Thermodynamic and structural effects of conformational constraints in protein-ligand interactions. Entropic paradoxy associated with ligand preorganization. J Am Chem Soc 131, 16758-16770 (2009).
16. Lokesh, G. L., Muralidhara, B. K., Negi, S. S. & Natarajan, A. Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design. J Am Chem Soc 129, 10658-10659 (2007).
17. Yuan, Z., Kumar, E. A., Kizhake, S. & Natarajan, A. Structure-activity relationship studiestoprobe the phosphoprotein binding siteonthe carboxy terminal domains of the breast cancer susceptibility gene 1. J Med Chem 54, 4264-4268 (2011).
18. Yuan, Z. et al. Exploiting the P-1 pocket of BRCT domains toward a structure guided inhibitor design. ACS Med Chem Lett 2, 764-767 (2011).
19. Simeonov, A. et al. Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal Biochem 375, 60-70 (2008).
20. Peschard, P. & Park, M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 3, 519-523 (2003).
21. Ogawa, S. et al. Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. Clin Cancer Res 16, 3825-3831 (2010).
22. Sanada, M. et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460, 904-908 (2009).
23. Mohapatra, B. et al. Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta 1833, 122-139 (2012).
24. Kumar, E. A. et al. Peptide truncation leads to a twist and an unusual increase in affinity for casitas B-lineage lymphoma tyrosine kinase binding domain. J Med Chem 55, 3583-3587 (2012).
25. Cowan, P. M. & McGavin, S. Structure of poly-L-proline. Nature 176, 470-478 (1955).
26. MacArthur, M. W. & Thornton, J. M. Influence of proline residues on protein conformation. J Mol Bio 218, 397-412 (1991).
27. Stapley, B. J. & Creamer, T. P. A survey of left-handed polyproline II helices. Protein Sci 8, 587-595 (1999).
28. Zhang, R. & Madalengoitia, J. S. Conformational stability of proline oligomers. Tetrahedron Lett 37, 6235 (1996).
29. Zhang, R., Brownewell, F. E. & Madalengoitia, J. S. A (1, 3) like strain as a key conformational control element in the design of poly-L-proline type II peptide mimics. J Am Chem Soc 120, 3894 (1998).
30. Zhang, R. et al. Poly-L-proline type II peptide mimics as probes of the active site occupancy requirements of cGMP-dependent protein kinase. J Pept Res 66, 151-159 (2005).
31. Mamai, A., Zhang, R., Natarajan, A. & Madalengoitia, J. S. Poly-L-proline type II peptide mimics based on the 3-azabicyclo[3.1.0]hexane system. J Org Chem 66, 455-460 (2001).
32. Meng, W., Sawasdikosol, S., Burakoff, S. J. & Eck, M. J. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature 398, 84-90 (1999).
33. Zheng, N., Wang, P., Jeffrey, P. D. & Pavletich, N. P. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 102, 533-539 (2000).
34. Ng, C. et al. Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates. Embo J 27, 804-816 (2008).
35. Kumar, E. A., Charvet, C. D., Lokesh, G. L. & Natarajan, A. High-throughput fluorescence polarization assay to identify inhibitors of Cbl (TKB)-protein tyrosine kinase interactions. Anal Biochem 411, 254-260 (2011).
36. Mamai, A., Hughes, N. E., Wurthmann, A. & Madalengoitia, J. S. Synthesis of conformationally constrained arginine and ornithine analogues based on the 3-substituted pyrrolidine framework. J Org Chem 66, 6483-6486 (2001).
37. Kiefhaber, T., Bachmann, A. & Jensen, K. S. Dynamics and mechanisms of coupled protein folding and binding reactions. Curr Opin Struct Biol 22, 21-29 (2012).
38. Vagin, A. & Teplyakov, A. An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr 56, 1622-1624 (2000).
39. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67, 235-242 (2011).
40. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67, 355-367 (2011).
41. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486-501 (2010).
42. Nikolovska-Coleska, Z. et al. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal Biochem 332, 261-273 (2004).
43. Pedretti, A., Villa, L. & Vistoli, G. VEGA - An open platform to develop chemobio-informatics applications, using plug-in architecture and script programming. Journal of Computer-Aided Molecular Design 18, doi:10.1023/B: JCAM.0000035186.90683.f2 (2004).
44. Hornak, V. et al. Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65, 712-725 (2006).
45. Case, D. A. et al. The Amber biomolecular simulation programs. J Comput Chem 26, 1668-1688 (2005).
46. Phillips, J. C. et al. Scalable molecular dynamics with NAMD. J Comput Chem 26, 1781-1802 (2005).
47. Homeyer, N., Horn, A. H., Lanig, H. & Sticht, H. AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine. J Mol Model 12, 281-289 (2006).
48. Bradbrook, G. M. et al. X-ray and molecular dynamics studies of concanavalin-A glucoside and mannoside complexes - Relating structure to thermodynamics of binding. Journal of the Chemical Society - Faraday Transactions 94, 1603-1611 (1998).
49. Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J Comput Chem 25, 1157-1174 (2004).
50. Jorgensen, W. L., Chandrasekhar, J., Madura, J. D., Impey, R. W. & Klein, M. L. Comparison of simple potential functions for simulating liquid water. Journal of Chemical Physics 79, 926-935, doi:10.1063/1.445869 (1983).
51. Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31, 455-461 (2010).
52. Delano, W. L. PyMOL User's Guide. (DeLano Scientific LLC, 2004).